by Truveta staff | Apr 21, 2025 | Data
Asthma is one of the most studied chronic diseases in medicine, yet decades into the biologics era, researchers face familiar frustrations. Limited phenotyping, unpredictable treatment responses, persistent health disparities, and slow insight cycles can’t meet...
by Truveta staff | Apr 1, 2025 | Research
GLP-1 drugs like Ozempic and Zepbound are transforming obesity treatment, yet 40-85% of patients are plagued by adverse GI events—particularly women. New research from Olio Labs, using Truveta Data, reveals that women experience nausea and vomiting at significantly...
by Truveta staff | Mar 20, 2025 | Data
Why autoimmune research needs better real-world data Biologics like Humira, Enbrel, and Rinvoq have transformed autoimmune treatment, revolutionizing treatment for patients with chronic inflammatory infections. However, the traditional methods of studying these...
by Truveta staff | Feb 4, 2025 | Data
The start of a new year can be a time for fresh beginnings and new resolutions. Yet for many, it also brings a renewed struggle with anxiety and depression. The cold, dark days of winter, combined with post-holiday stress and lingering financial pressures, can make...
by Jay Nanduri | Dec 10, 2024 | Technology
In the final article in this series, I will share some thoughts on meeting the following challenge: How to rapidly support new AI scenarios and adjacencies through reuse and transfer learning? Truveta has diverse, multimodal, and up-to-date data on clinical...
